135 related articles for article (PubMed ID: 16997147)
1. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation.
MacKenzie NM
Drug Discov Today; 2006 Oct; 11(19-20):952-6. PubMed ID: 16997147
[TBL] [Abstract][Full Text] [Related]
2. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
3. Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis.
Strand V
Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):8, 13-4. PubMed ID: 17491581
[No Abstract] [Full Text] [Related]
4. T-cell-targeted therapies in rheumatoid arthritis.
Weyand CM; Goronzy JJ
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):201-10. PubMed ID: 16932686
[TBL] [Abstract][Full Text] [Related]
5. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
6. Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent.
Srinivasan M; Eri R; Zunt SL; Summerlin DJ; Brand DD; Blum JS
Arthritis Rheum; 2007 Feb; 56(2):498-508. PubMed ID: 17265485
[TBL] [Abstract][Full Text] [Related]
7. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance.
Wang Q; Sun B; Wang D; Ji Y; Kong Q; Wang G; Wang J; Zhao W; Jin L; Li H
Scand J Immunol; 2008 Dec; 68(6):607-15. PubMed ID: 18959624
[TBL] [Abstract][Full Text] [Related]
8. Early rheumatoid arthritis.
Machold KP; Nell V; Stamm T; Aletaha D; Smolen JS
Curr Opin Rheumatol; 2006 May; 18(3):282-8. PubMed ID: 16582693
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7 in rheumatoid arthritis.
Churchman SM; Ponchel F
Rheumatology (Oxford); 2008 Jun; 47(6):753-9. PubMed ID: 18356170
[TBL] [Abstract][Full Text] [Related]
11. Targeting IL-17 and Th17 cells in rheumatoid arthritis.
Sarkar S; Fox DA
Rheum Dis Clin North Am; 2010 May; 36(2):345-66. PubMed ID: 20510238
[TBL] [Abstract][Full Text] [Related]
12. Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Malmström V; Trollmo C; Klareskog L
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S15-20. PubMed ID: 15833144
[TBL] [Abstract][Full Text] [Related]
13. Targeting of cells involved in the pathogenesis of rheumatoid arthritis.
Panayi GS
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():8-10. PubMed ID: 10646482
[TBL] [Abstract][Full Text] [Related]
14. Cytokine networks--towards new therapies for rheumatoid arthritis.
McInnes IB; Liew FY
Nat Clin Pract Rheumatol; 2005 Nov; 1(1):31-9. PubMed ID: 16932625
[TBL] [Abstract][Full Text] [Related]
15. CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade.
Graca L
Acta Reumatol Port; 2008; 33(3):267-76. PubMed ID: 18846007
[TBL] [Abstract][Full Text] [Related]
16. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis. Understanding joint damage and inflammation.
Capriotti T
Adv Nurse Pract; 2007 May; 15(5):61-2, 64-6, 94. PubMed ID: 20000214
[No Abstract] [Full Text] [Related]
18. [Participation of T lymphocytes in the development and perpetuation of rheumatoid arthritis].
Pablos Álvarez JL
Reumatol Clin; 2011; 7(6):352-3. PubMed ID: 22078692
[No Abstract] [Full Text] [Related]
19. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
Renato GM
Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of the costimulatory molecules CD80, CD86, CD152, PD-1 and ICOS on T-cells from paracoccidioidomycosis patients: lack of correlation with T-cell hyporesponsiveness.
Cacere CR; Mendes-Giannini MJ; Fontes CJ; Kono A; Duarte AJ; Benard G
Clin Immunol; 2008 Nov; 129(2):341-9. PubMed ID: 18757242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
